Impaired Vasoreactivity in DOX-Induced Cardiotoxicity
This study used a novel computed tomography (CT) methodology to demonstrate impaired adenosine (ADE)- and dobutamine (DOB)-induced coronary vasoreactivity in a large animal model of chronic doxorubicin (DOX)-induced cardiotoxicity. Left ventricular ejection fraction (LVEF) was not reduced until a cumulative DOX dose of 12 to 15 mg/kg was administered. Impairment in ADE-induced vasodilator responses occurred early in the progression of DOX-induced cardiotoxicity similar to impairment in global longitudinal strain (GLS). 2D = 2-dimensional; TTE = transthoracic echocardiography.